Mary Reed
Hematology & Oncology · Flushing, NYNPI 1043393523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 76 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$232
- Johnson & Johnson$221
- Daiichi Sankyo Inc.$191
- Astellas Pharma US Inc$122
- Lilly USA, LLC$93
- Bristol Myers Squibb$92
- plus $718 from 18 others
What the payments were for
- Food & beverage$1,65799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $232 |
| Johnson & Johnson(2 entities) | 9 | $221 |
| Daiichi Sankyo Inc. | 8 | $191 |
| Astellas Pharma US Inc | 5 | $122 |
| Lilly USA, LLC | 4 | $93 |
| Bristol Myers Squibb | 4 | $92 |
| Bayer | 4 | $87 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Incyte Corporation | 4 | $81 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $55 |
| AbbVie | 2 | $51 |
| Janssen Scientific Affairs, LLC | 2 | $44 |
| Pfizer | 3 | $40 |
| Gilead | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Novartis | 1 | $28 |
| Taiho Oncology, Inc. | 1 | $25 |
| Puma Biotechnology, Inc. | 1 | $25 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Sanofi | 1 | $21 |
| Merck | 1 | $21 |
| Amgen | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Tesaro, Inc. | 1 | $18 |
How this compares
$1,669 in reported general payments places this provider in the 50th percentile of 967 hematology & oncology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $166,648 |
| Exemestane | 18 | $2,595 |
| ClopidogrelClopidogrel Bisulfate | 23 | $79 |
| Hydrochlorothiazide | 23 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $122 | $166,64812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Flushing
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.